Mark Krueger, MPH, founded MK&A (Mark Krueger & Associates, Inc.) in 1996 to help pharmaceutical, biotech, device and diagnostic companies create the best patient engagement and patient advocacy programs. Under Mark’s direction, MK&A has a singular focus on helping clients develop mutually beneficial relationships with diverse groups and individuals who are essential to research and development, appropriate use and access. The firm has demonstrated repeatedly that integration of external voices creates better health care for all.
MK&A has 20 years of extensive experience in the design of early access programs, having designed and delivered 25 compliant and efficient programs and policies in cancer, orphan indication, AIDS, and other diseases. These programs include the largest early access program for a cancer compound and innovative responses for demand for orphan medicines. MK&A has also helped define appropriate pre-approval access to cell and gene therapy. Many companies’ policies on pre-approval access, planning and implementing one of the largest pre-approval drug access program, reflect the firm’ input.
Mark holds a BA from the College of Columbia University and an MPH from Columbia’s Joseph A. Mailman Graduate School of Public Health.